AnaptysBio (ANAB) shares were up Monday morning after the company said its board approved a stock repurchase plan of up to $75 million, expiring Dec. 31.
The company said that as of Dec. 31, it had cash, cash equivalents and investments of more than $420 million, which are expected to fund its research and development plan through 2027.
The clinical-stage pharmaceutical company said it expects a $75 million commercial sales milestone payment from GSK (GSK) in 2025 or 2026.
Price: 19.94, Change: +2.86, Percent Change: +16.74
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。